Roche

Roche’s trontinemab shows strong early promise in Alzheimer’s, with improved brain delivery, biomarker response, and safety…

While prasinezumab missed its primary endpoint, time-to-event analyses suggest potential in delaying early Parkinson’s disease…

The initiative, driven by Cancer Research and Statistic Foundation and supported by AstraZeneca, Pfizer and Roche, and lab partner…

The revival of CNS drug development is being fueled by advancements in neuroimmunology and neurodegeneration, moving beyond…

Novel therapies and regulatory shifts drive growth in the Duchenne muscular dystrophy market, with exon-skipping therapies leading…

The decision, made in response to Roche's appeal on October 16, 2024, reversed an earlier order from October 9, 2024

GlobalData reports the rise in HER2+ breast cancer cases, stressing the importance of cost-effective biosimilars as Zydus and…

The data showcases Vabysmo’s efficacy in wet age-related macular degeneration (wAMD) and diabetic macular edema (DME)

GlobalData’s patient-based forecast reveals that the BRAF inhibitor market for melanoma will reach a key milestone by 2028, with…

If approved, glofitamab would be the first fixed-duration CD20xCD3 T-cell engaging bi-specific antibody approved to treat the most…